Pantarol (Pantoprazole)

Pantoprazole, the active ingredient in Pantarol, is a proton pump inhibitor presented as an injectable solution for intravenous use. It treats conditions related to excess gastric acid production in adults, such as gastro‑oesophageal reflux disease, erosive oesophagitis, peptic ulcer disease and provides stress‑ulcer prophylaxis.

GNH USA supplies Pantarol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pantarol, a proton pump inhibitor, acts on the gastric acid‑secreting pathway to control hyperacidity disorders. - Gastro‑oesophageal reflux disease (GERD): reduces acid exposure and improves heart‑burn symptoms. - Erosive oesophagitis: promotes healing of inflamed oesophageal mucosa. - Peptic ulcer disease: facilitates ulcer closure and prevents recurrence. - Stress ulcer prophylaxis: lowers risk of gastric lesions in critically ill patients.

Adverse reactions may occur with any dosage form of pantoprazole.

Common Side Effects: - Headache: mild to moderate intensity. - Diarrhoea: watery stools, usually transient. - Nausea: occasional upset stomach. - Abdominal pain: cramping or discomfort. - Flatulence: increased gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with rash, swelling, and breathing difficulty. - Clostridioides difficile infection: severe colitis presenting with watery diarrhoea. - Hypomagnesemia: low serum magnesium causing muscle cramps or arrhythmia. - Hepatic enzyme elevation: increased ALT/AST levels. - Stevens‑Johnson syndrome/toxic epidermal necrolysis: severe skin reactions. - Cardiac arrhythmias: rare but potentially life‑threatening rhythm disturbances.

Before initiating therapy, consider the following safety measures. - Renal impairment: monitor renal function and adjust therapy if needed. - Hepatic impairment: use with caution; assess liver enzymes periodically. - Pregnancy: Category B – discuss potential benefits and risks with the prescriber. - Concomitant antiplatelet or anticoagulant therapy: monitor for increased bleeding risk. - Long‑term use: evaluate the necessity regularly to avoid unnecessary exposure. - Store at 2‑8°C: keep refrigerated, protect from light, do not freeze or shake.

Pantoprazole may affect the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid): - Clopidogrel: reduced antiplatelet effect, may increase cardiovascular events. - Atazanavir: markedly decreased absorption, compromising antiviral efficacy. - Warfarin: potential increase in INR, requiring closer anticoagulation monitoring.

Moderate Interactions (Monitor Closely): - Methotrexate: increased serum levels, risk of toxicity. - Digoxin: elevated concentrations, monitor for signs of digoxin toxicity. - Phenytoin, carbamazepine, diazepam: possible reduction in plasma levels, consider dose adjustments.